Tucson, AZ – August 20, 2025 – Questex Fierce Biotech – shared by Reglagene, Inc.
The first half of 2025 was brutal for biotech, but investors remain keen on therapeutics in several indications, and silver linings exist, particularly for private companies.
“You’ve got a market industry that is already facing a lot of challenges,” Omar Khalil, managing director at early-stage investor Santé Ventures, recently told Fierce Biotech. “And then you just kind of inject every type of uncertainty and volatility within a very short timeframe.”
In less than six months, President Donald Trump’s administration overhauled federal health agencies with mass layoffs, research grant cancellations, and leadership changes. The president also introduced the potential of pharmaceutical import tariffs and drug pricing reform to the broader biopharma market.